Generated by AI
Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response. The company also advances CHOICE, a discovery and development platform, alongside a broader pipeline of engineered virus-based product candidates. Genelux serves the oncology market through drug research, development, and clinical trial services centered on immuno-oncology applications. Headquartered in Westlake Village, California, Genelux Corporation concentrates on current therapeutic programs and specialty biotechnology solutions aimed at addressing unmet needs in cancer treatment.
Website2625 Townsgate Road
Westlake Village, CA, 91361
United States
The latest articles about GNLX.
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung cancer -- -- Olvi-Vec systemic development programs continue to advance in SCLC and NSCLC, with additional dose-escalation updates expected by year-end 2026 -- -- $15.5 million in pro forma cash and inves
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Genelux, exceeding the reduction achieved following first-line therapy -- -- Findings support the potential of systemically administered Olvi-Vec to drive anti-tumor activity and enhance responsiveness t
Summary of Jan 8's posts. Generated by AI.
No summary yet.
Summary of Mar 7's posts. Generated by AI.
Summary of Mar 7's posts. Generated by AI.
Investors talking about GNLX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.